Type 2 Diabetes

Data show metformin was associated with reduced odds of developing AMD, with low to moderate doses having the greatest potential benefit.

An analysis comparing prescribing practices for Medicare Advantage beneficiaries against those in fee-for-service programs suggests Advantage patients were more likely to receive ACE inhibitors or ARBs, but 20% less likely to receive GLP-1 RAs and 9% less likely to receive SGLT2 inhibitors.

An analysis from investigators in Sweden suggests patients with acromegaly with diabetes had a 58% greater risk of overall mortality and a more than 2-fold increase in risk of cardiovascular mortality compared to their counterparts without diabetes.

The Optimal screening ages for two measurements were 2 years and 6 years for the diagnosis of clinical type 1 diabetes.

There was no association found between ever using metformin and the risk of either IBD, Crohn’s disease, or ulcerative colitis.

An analysis of nationally representative data from NHANES cycles from 1999-2000 through 2017-2018 suggests just 6.8% of US adults had optimal cardiometabolic health.

New data from a study performed by investigators at UVA Health details the accuracy of blood glucose measurements with factory-calibrated CGMs in patients undergoing dialysis.

With the first 6 months of 2022 behind us, Endocrinology Network has compiled a list of the top approvals in diabetes care from the first half of the year. The list includes multiple approvals for CGM, a first-in-class agent, and an increased dose of a popular GLP-1 RA.

Varenicline was efficacious at weeks 12, 24, and 52 of the trial compared with placebo in a smoking cessation program.

An analysis from Duke University School of Medicine suggests few PCPs were performing fundoscopy to identify diabetic retinopathy in patients with type 2 diabetes and even those who did were often accurate just 63% of the time.

Dr. Jennifer Green led a panel in discussing new treatments and topics in diabetes care.

After using eye care examination results as a reference standard, the accuracy of PCP fundoscopic examination was 62.7%.

At HiD 2022, Dr. Budoff discusses the use and utility of coronary calcium scoring for risk stratification

Dr. Martin explores the explosion of new consumer technologies and how to close the gap in disparities between data collection and using the data in practice.

An analysis of real-world data from more than 6500 patients suggests insulin users had a greater risk of fracture than patients using metformin, but this became attenuated among patients using a combination of insulin and metformin.

Dr. Ray discusses the impact of current practice on cholesterol goal attainment and what more needs to be done.

Dr. Green discusses the potential of combination therapy to reduce cardiovascular and kidney outcomes in people with type 2 diabetes.

Dr. Joseph discusses modalities to address cardiometabolic disease in individuals around the country, from lifestyle management to policy-level changes.

In this episode, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss their experiences with prescribing tirzepatide (Mounjaro) and what issues patients have encountered, the prospect of new biosimilar insulins that may be coming to the market, and the misdiagnosis of type 1 diabetes in adult patients.

Dr. Gregory Weiss provides perspective on recent data detailing the acceleration of heart failure progression associated with a diagnosis of diabetes mellitus.

There were also significant social determinants including race and religion discordance between the healthcare provider and patient and caregiver responsibilities toward others.

An analysis of data from Medicare Fee-for-Service beneficiaries suggests patients attending annual wellness visits were 36% less likely to require lower limb amputation than their counterparts who did not attend an annual wellness visit that year.

An analysis of the National Inpatient Sample details the statistically significant increases in the risk of experiencing myocardial infarction, PCI, or CABG in patients with prediabetes compared to their normoglycemic counterparts.

Erika Petersen, MD, discusses 24-month data from SENZA-PDN and provides perspective on the potential for spinal cord stimulation for reducing pain from diabetic peripheral neuropathy in real-world settings.

An analysis of 20 randomized clinical trials comparing empagliflozin against placebo therapy in patients with type 2 diabetes suggests use of the SGLT2 inhibitor could reduce risk of developing kidney stones by nearly 40%.

An analysis of the SEARCH for Youth in Diabetes presented at ENDO 2022 details historic and contemporary disparities in insulin pump use for pediatric type 1 diabetes based on racial/ethnic background, household income, and insurance type.

On June 12, the Endocrine Society released new guidance for management of hyperglycemia in adult patients in noncritical care settings, which are cosponsored by the AACE, ADA, ADCES, and ESE.

An analysis of the National Inpatient Sample at ENDO 2022 provides insight into the risk of myocardial infarction associated with prediabetes compared against normoglycemic patients.

In the fourth and final episode from ADA 2022, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, take a deep dive into the meeting from their perspectives as a clinical pharmacy specialist and a nurse practitioner, including their picks for the most exciting advances in diabetes technology to come from the year’s largest diabetes meeting.